

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **1** of **4** Attorney Docket Number **MCY5USA**

Complete if Known

Application Number	10/584,207
Filing Date	November 28, 2007
First Named Inventor	Terence J. Colgan
Art Unit	1649
Examiner Name	Borgeest, C. M.

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,228,596	05-08-2001	Macina	
	2	US-2010-0172838	07-08-2010	Siu	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	3	WO2008/049239	05-02-2008	Siu		
	4	WO2005/061725	07-07-2005	Colgan		
	5	WO2007/081767	07-19-2007	Moore		
	6	WO2002/009573	02-07-2002	Mutter		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/584,207
				Filing Date	November 28, 2007
				First Named Inventor	Terence J. Colgan
				Art Unit	1649
				Examiner Name	Borgeest, C. M.
Sheet	2	of	4	Attorney Docket Number	MCY5USA
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	7	SHAARAWY et al, Biomarkers of intrinsic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer, Acta Oncologica, 40(4):513-8 (January 2001)			
	8	DESMOND et al, Identification of genes differentially expressed in endometrial carcinoma, Proceedings of the American Association for Cancer Research Annual Meeting, 44:1198 (July 2003)			
	9	HARDT et al, Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls, Database Biosis Accession No. PREV200300402239, Anticancer Research, 23(2a):851-4 (March 2003)			
	10	DESOUZA et al, Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cLCAT with multidimensional liquid chromatography and tandem mass spectrometry, Journal of Proteome Research, 4(2):377-86 (March 2005)			
	11	DRAPKIN R., et al, Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas, Cancer Research, Vol. 65, No. 6, pages 2162-2169 March 15, 2005			
	12	LI H et al, Identification of Candidate Biomarker Proteins Released by Human Endometrial and Cervical Cancer Cells Using Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry, Journal of Proteome Research, Vol. 6, No. 7, pages 2615-2622, May 25, 2007			
	13	ONO K et al, Identification by cDNA Microarray of Genes Involved in Ovarian Carcinogenesis, Cancer Research, Vol. 60, pages 5007-5011, September 15, 2000			
	14	HELLSTROM et al, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Research, 63(13):3695-3700 (July 2003)			
	15	ACE, "Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase", Reproductive Biology and Endocrinology, 2:54-62, July 2004			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
Sheet	3	of	4	Application Number	10/584,207	
				Filing Date	November 28, 2007	
				First Named Inventor	Terence J. Colgan	
				Art Unit	1649	
				Examiner Name	Borgeest, C. M.	
				Attorney Docket Number	MCY5USA	
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
	16	ABDUL-RAHMAN, "Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods", Electrophoresis, 28(12):1989-1996, June 2007				
	17	REID-NICHOLSON, "Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis", Modern Pathology, 19(8):1091-1100, Epub April 28, 2006, August 2006				
	18	FERGUSON, "Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles", Clinical Cancer Research, 11(6):2252-2257, March 15, 2005				
	19	HEBBAR, "Differential expression of MUC genes in endometrial and cervical tissues and tumors", BMC Cancer. 5:124-135, September 27, 2005				
	20	LI, "Is the measurement of placental protein-14 and CA-125 in plasma and uterine flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding?", Human Reproduction, 13(10):2895-2901, October 1998				
	21	DeSOUZA, "Proteomic analysis of the proliferative and secretory phases of the human endometrium: protein identification and differential protein expression", Proteomics, 5(1):270-281, January 2005				
	22	MUTTER, "Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation", Gynecologic Oncology 83(2):177-185, November 2001				
	23	LALITKUMAR, "Placental protein 14 in endometrium during menstrual cycle and effect of early luteal phase mifepristone administration on its expression in implantation stage endometrium in the rhesus monkey", Human Reproduction, 13(12):3478-3486, December 1998				
	24	GALGANO, "Comprehensive analysis of HE4 expression in normal and malignant human tissues", Modern Pathology, 19(6):847-853, June 2006: E-pub April 7, 2006				
	25	ZIERAU, "Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus", Endocrine-Related Cancer, 11(4):823-830, December 2004				
Examiner Signature				Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	4	Application Number	10/584,207
				Filing Date	November 28, 2007
				First Named Inventor	Terence J. Colgan
				Art Unit	1649
				Examiner Name	Borgeest, C. M.
				Attorney Docket Number	MCY5USA
OTHER INFORMATION SUBMITTED FOR CONSIDERATION BY THE OFFICE (37 CFR §1.98(a)(1))					
Examiner Initials*	Cite No. ¹	For unpublished applications, include the name of the inventor (in CAPITAL LETTERS), US serial number, and filing date.			T ²
	26	Extended European Search Report issued with Communication dated May 25, 2011 in related EP application No. 10169645.8			
	27	International Search Report dated May 11, 2005 issued in corresponding International application no. PCT/CA2004/002172			
	28	International Preliminary Report on Patentability dated June 26, 2006 issued in corresponding International application no. PCT/CA2004/002172			
	29	European Search Report dated April 7, 2008 issued in corresponding EP application No. 04802347.7			
	30	Communication dated September 9, 2008 issued in corresponding EP application No. 04802347.7			
	31	Applicant's response to communication dated September 9, 2008 filed on June 29, 2009 in corresponding EP application No. 04802347.7			
	32	International Preliminary Report on Patentability dated April 28, 2009 issued in related International application no. PCT/CA2007/001935			
	33	International Search Report dated February 22, 2008 issued in related International application no. PCT/CA2007/001935			
	34	Supplemental European Search Report dated September 15, 2010 issued in related EP application no. 07816085.0			
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.